Head and Neck Cancer Clinical Trial
— CAHNCAOfficial title:
A Comprehensive Assessment of Adult Head and Neck Cancer Survivors (A Pilot Study)
Cancer survivorship has dramatically improved within the last four decades and a greater
number of Americans are living after cancer diagnosis. An increase in the number of
survivors has highlighted the need to investigate the quality of life experienced by these
survivors. While Survivorship research has improved our understanding of the challenges
faced by some cancer survivors, there is a paucity of research on the functional and
cognitive health status of head and neck cancer survivors.
The purpose of this study is to evaluate the functional and cognitive changes that occur in
head and neck cancer patients as a result of cancer treatment, in an attempt to increase our
understanding of the complex interactions between cancer treatment, comorbid health ailments
and quality of life.
Status | Completed |
Enrollment | 15 |
Est. completion date | February 2012 |
Est. primary completion date | February 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - Subjects must be 40 years of age or older. - Subjects must be able to read, write and speak English fluently. - Subjects must be newly diagnosed with head and neck squamous cell cancer. - Subjects must not have already had treatment for this cancer diagnosis. - Subjects must be anticipated to receive at least one of the following types of therapy: surgery, chemotherapy or radiation. Exclusion Criteria: - Subjects with prior cancer diagnoses who have evidence of active disease. - Subjects who have received cancer treatment within the past year. - Subjects who have received chemotherapy or radiation treatment within the past year (for any disease state). - Life expectancy of less than 3 months. - Subjects with melanoma or other non-squamous cell cancer. - Subjects who score >9 on Short Blessed Test (SBT) at baseline. - Subjects who are unable to complete all of the required forms and tasks at baseline, either because of cognitive deficits or physical limitations. - Any medical condition the PI determines to affect safe study participation. |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | Washington University School of Medicine | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Jay F. Piccirillo, MD | University of Alabama at Birmingham |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Functional and Cognitive health status | At the time of cancer diagnosis and Within 1 month of cancer therapy | No | |
Secondary | Assess the effectiveness of novel performance-based tests in detecting subtle functional and cognitive health status changes | At the time of cancer diagnosis and Within 1 month of cancer therapy | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |